Abstract Details

Title Wearable Sensors for Quantitative Motor Assessments in Multiple System Atrophy

Topic Neuromuscular and Clinical Neurophysiology (EMG)

Presentation(s) P8 - Poster Session 8 (11:45 AM-12:45 PM)

Poster/Presentation
Number 4-002

Objective To determine the utility of quantitative wearable sensors in Multiple system atrophy (MSA).

Background Symptoms of MSA include parkinsonism, ataxia, and/or failure of the autonomic nervous system. Wearable sensors have potential to characterize motor impairment in an outpatient setting and to serve as clinical trial outcomes in MSA.

Design/Methods Participants enrolled in biomarkers of progression in MSA (bioMUSE) had early MSA (<3 years of motor symptoms) by clinical assessment. All completed neurologic exam, neuroimaging and biofluid assessments. The Unified MSA Rating Scale motor exam (UMSARS II), Parkinson Plus Scale (PPSm), and Tandem Walk (TW), were completed every 3 months. PAMSys actigraphy sensors were worn continuously for up to 12-months to assess gait (step count, bouts of walking, steps per bout, cadence, cadence variability), postures (minutes of sitting, lying, standing, walking, sedentary [sitting + lying]) and postural transitions (sit-to-stand) by averaging data over 14-days. Pearson correlation coefficients between clinical and sensor variables were estimated at each time point and two-sided p-values were calculated.

Results 12 participants (6 Female, mean age 64.2) with motor symptoms of 2.X years were followed for ≥ 6 months (n=9), and 12 months (n=5). Significant (P<0.05) correlations were observed between step count, bouts of walking, minutes walking and sit to stand transitions for UMSARS II, PPSm and TW. Significant correlations were most frequently observed at BL and months 3, 6 and 9. The strongest correlations (r>0.8) were observed at month 6 and 9. The PPSm had more frequent and stronger correlation with sensor parameters than UMSARS II.

Conclusions In early MSA, continuous actigraphy is feasible and demonstrates significant correlation with motor exam. The PPSm appeared to have stronger correlation with sensor variables than UMSARS II. Continuous motor assessments via wearable sensors may be a suitable endpoint for clinical trials in MSA.

Authors/Disclosures
Daniel O. Claassen, MD, FAAN (Vanderbilt University Medical Center) PRESENTER	Dr. Claassen has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Alterity. Dr. Claassen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Claassen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. Dr. Claassen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for AskBio. Dr. Claassen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for University of Michigan. Dr. Claassen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cognition Therapeutics . Dr. Claassen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amylyx. The institution of Dr. Claassen has received research support from NIH. The institution of Dr. Claassen has received research support from CHDI. The institution of Dr. Claassen has received research support from HDSA. The institution of Dr. Claassen has received research support from Department of Defense. The institution of Dr. Claassen has received research support from CHDI.
Jessie Iregui	Miss Iregui has nothing to disclose.
Amy Wynn, NP (Vanderbilt University Medical Center)	Ms. Wynn has nothing to disclose.
	No disclosure on file
Cynthia Wong	Cynthia Wong has received personal compensation for serving as an employee of Alterity Therapeutics. An immediate family member of Cynthia Wong has received personal compensation for serving as an employee of RefleXion Medical. Cynthia Wong has stock in Teva. An immediate family member of Cynthia Wong has stock in 10x Genomics.
David A. Stamler, MD (Alterity Therapeutics)	Dr. Stamler has received personal compensation for serving as an employee of Alterity Therapeutics. Dr. Stamler has stock in Alterity Therapeutics.

��ɫ��

��ɫ��